India Breast Cancer Treatment Market Assessment, By Type [Ductal Carcinoma In Situ, Invasive Ductal Carcinoma, Lobular Carcinoma In Situ, Invasive Lobular Cancer, Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Breast

India breast cancer treatment market is projected to witness a CAGR of 11.17% during the forecast period FY2026-FY2033, growing from USD 505.78 million in FY2025 to USD 1179.66 million in FY2033. The market’s growth is augmented by the rising cases of breast cancer in the country, increasing efforts of research organizations to introduce advanced therapeutic solutions to combat breast cancer, and novel launches by leading players of the market. According to the Global Cancer Observatory, IARC-WHO, 2022, 98,337 deaths occurred due to breast cancer among females in 2022 in India.

The accessibility of breast cancer treatment is increasing across India due to the rising government initiatives, focus on improving healthcare infrastructure, and growing awareness about the condition. Advancements in medical technology and the introduction of innovative therapies, including targeted therapies, immunotherapies, and antibody-drug conjugates, are broadening the range of effective treatment options available in India. Additionally, the establishment of specialized cancer centers and improved diagnostic facilities are ensuring better disease management and positively influencing the market’s expansion. Meanwhile, late-stage diagnosis in several cases, high costs of treatment, and lack of oncologists in the country pose challenges to the market’s growth.

Increasing Efforts to Improve Breast Cancer Diagnosis Boosts Market Growth

Rising efforts to ensure early detection of breast cancer across the country are propelling the market’s expansion as they are allowing the identification of cases at more treatable stages, augmenting the demand for treatment services. For instance, in November 2024, a team of oncologists under the Cancer Mukt Bharat campaign launched India’s first 24x7 free Pink Cancer Helpline for promoting early detection of breast cancer. The helpline offers guidance via video and phone consultations, including preventive advice and self-examination instructions at no cost. Such initiatives promote awareness about breast cancer, reduce delays, and improve patient access to diagnostic technologies, in turn propelling the expansion of the market.

Increasing Research Efforts of Educational Organizations Support Market Expansion

Rising research efforts by educational organizations are fostering innovation, improving early detection of breast cancer, and enhancing patient outcomes. Institutions like the Cancer Research Institute at the Himalayan Institute of Medical Sciences has launched specialized clinics, including India’s first Young Breast Cancer Clinic, to address the unique requirements of younger patients. Such efforts provide tailored care, promote targeted research, and set new benchmarks for breast cancer treatment and awareness.

Additionally, increasing research efforts are allowing institutes to receive approvals and patents, further encouraging different organizations to continue on with their research efforts. For instance, in February 2025, researchers from IIT Madras successfully developed and patented a next generation drug delivery system for treating breast cancer. The patented technology encapsulates anti-cancer drugs in the nanoparticles that directly target cancer cells, reducing side effects and minimizing damage to healthy tissues.

Development of New Breast Cancer Therapies is Driving the Market’s Growth

The growing efforts of pharmaceutical companies and research organizations to boost the introduction of innovative breast cancer therapies in India is positively influencing the market’s expansion. The availability of novel treatment solutions allows medical professionals to address the critical unmet requirements of the patient population and ensures that patients who previously had limited treatment options available have access to advanced therapies.

Research institutions across India are focusing on developing advanced therapies to improve drug delivery systems in order to combat the rising cases of breast cancer in the country. For instance, in January 2025, researchers from Institute Kolkata and IIT Guwahati developed an innovative injectable hydrogel for targeted breast cancer therapy. The hydrogel releases anti-cancer drugs in a controlled manner. The hydrogel reduces damage to healthy cells and minimizes systemic side effects by ensuring the delivery of chemotherapy drugs directly in the tumor sites.

Hospitals Holds Major Market Share

Hospital account for a significant share of the market as they have access to advanced therapeutic solutions and diagnostic technologies, provide multidisciplinary care, and a comprehensive infrastructure. Additionally, hospitals are better equipped to participate in clinical trials and invest in new technologies, enhancing treatment outcomes. Hospitals also act as key locations for screening programs and cancer awareness, improving the rate of diagnosis and thus treatment uptake. Moreover, a rising number of cancer hospitals are being constructed across the country to ensure that the patient population is provided with the required treatment solutions, thus bolstering the market’s demand. For instance, in December 2024, the newly built Dr Sampat Kumar S. Shivangi Cancer Hospital was inaugurated in Karnataka. Such efforts are increasing the availability of advanced cancer care and improving diagnosis rates and treatment outcomes in underserved regions.

Impact of the U.S. Tariff on India Breast Cancer Treatment Market

Pharmaceutical exports have been exempted from the recent tariffs, however, the medical device industry, which is integral for early detection and treatment of cancer, is expected to face substantial challenges. Healthcare professionals might face challenges in procuring advanced equipment, hindering the diagnostic process, which is particularly crucial for ensuring effective treatment of breast cancer.

Additionally, the tariffs are going to impact Indian medical device manufacturers that export their products to the United States and result in decreased revenues, potentially limiting their resources for research and development activities, constraining the availability of novel diagnostic and therapeutic solutions.

Key Players Landscape and Outlook

The key players of the market are focusing on launching new drugs to aid the patient population in combating the disease and expanding their presence in the market. For instance, in January 2024, AstraZeneca Pharma India Limited launched Trastuzumab deruxtecan in India for treating adults with metastatic or unresectable HER2 positive breast cancer who have already received an anti-HER2 regimen. The introduction of this drug is seen as a major advancement, providing a transformative option for patients with aggressive breast cancer. Such launches address the critical unmet requirements of the patients by expanding the available treatment options.